{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=MACE",
    "query": {
      "condition": "MACE"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 28,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=MACE&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T09:41:09.015Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06098079",
      "title": "Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Obesity"
      ],
      "interventions": [
        {
          "name": "Naltrexone-Bupropion (NB) Combination",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Currax Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 8600,
      "start_date": "2024-01-03",
      "completion_date": "2029-07",
      "has_results": false,
      "last_update_posted_date": "2026-03-31",
      "last_synced_at": "2026-05-22T09:41:09.015Z",
      "location_count": 140,
      "location_summary": "Birmingham, Alabama • Cullman, Alabama • Mobile, Alabama + 111 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Cullman",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06098079"
    },
    {
      "nct_id": "NCT01103440",
      "title": "Aspirin Resistance and Percutaneous Coronary Intervention (PCI)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Stable Angina"
      ],
      "interventions": [
        {
          "name": "Intravenous Glycoprotein inhibitor + ASA, Clopidogrel",
          "type": "DRUG"
        },
        {
          "name": "Antiplatelet Therapy (ASA, Clopidogrel)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Icahn School of Medicine at Mount Sinai",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2007-04",
      "completion_date": "2009-06",
      "has_results": true,
      "last_update_posted_date": "2018-02-14",
      "last_synced_at": "2026-05-22T09:41:09.015Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01103440"
    },
    {
      "nct_id": "NCT05739383",
      "title": "A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Primary Prevention of Atherosclerotic Cardiovascular Disease"
      ],
      "interventions": [
        {
          "name": "Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL",
          "type": "DRUG"
        },
        {
          "name": "Placebo in 1.5ml",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "79 Years",
        "sex": "ALL",
        "summary": "40 Years to 79 Years"
      },
      "enrollment_count": 14012,
      "start_date": "2023-03-09",
      "completion_date": "2029-04-16",
      "has_results": false,
      "last_update_posted_date": "2026-04-14",
      "last_synced_at": "2026-05-22T09:41:09.015Z",
      "location_count": 243,
      "location_summary": "Birmingham, Alabama • Fairhope, Alabama • Foley, Alabama + 189 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fairhope",
          "state": "Alabama"
        },
        {
          "city": "Foley",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05739383"
    },
    {
      "nct_id": "NCT07162376",
      "title": "How Clinical and Personal Information Shape Physicians' Risk Judgments",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Major Adverse Cardiac Event (MACE)"
      ],
      "interventions": [
        {
          "name": "Personal Information Disclosure",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Maryland, College Park",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 300,
      "start_date": "2025-09-16",
      "completion_date": "2025-09-26",
      "has_results": false,
      "last_update_posted_date": "2026-01-16",
      "last_synced_at": "2026-05-22T09:41:09.015Z",
      "location_count": 1,
      "location_summary": "College Park, Maryland",
      "locations": [
        {
          "city": "College Park",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07162376"
    },
    {
      "nct_id": "NCT05605964",
      "title": "Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Relugolix",
          "type": "DRUG"
        },
        {
          "name": "Leuprolide Acetate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sumitomo Pharma America, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 387,
      "start_date": "2023-01-25",
      "completion_date": "2025-01-02",
      "has_results": false,
      "last_update_posted_date": "2025-08-17",
      "last_synced_at": "2026-05-22T09:41:09.015Z",
      "location_count": 108,
      "location_summary": "Mobile, Alabama • Tucson, Arizona • Little Rock, Arkansas + 83 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Downey",
          "state": "California"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05605964"
    },
    {
      "nct_id": "NCT04195139",
      "title": "Nivolumab and Temozolomide Versus Temozolomide Alone in Newly Diagnosed Elderly Patients With GBM",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma Multiforme"
      ],
      "interventions": [
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Sydney",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 103,
      "start_date": "2018-02-22",
      "completion_date": "2025-12-31",
      "has_results": false,
      "last_update_posted_date": "2024-12-11",
      "last_synced_at": "2026-05-22T09:41:09.015Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04195139"
    },
    {
      "nct_id": "NCT05821309",
      "title": "Evaluation of Fecal Microbiome Changes After Antegrade Continence Enema Placement and Initiation of Bowel Flush Regimen",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Constipation"
      ],
      "interventions": [
        {
          "name": "PEG 3350",
          "type": "DRUG"
        },
        {
          "name": "PEG-3350 with electrolytes",
          "type": "DRUG"
        },
        {
          "name": "Glycerin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Indiana University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "2 Years to 18 Years"
      },
      "enrollment_count": 65,
      "start_date": "2023-06-08",
      "completion_date": "2026-07",
      "has_results": false,
      "last_update_posted_date": "2025-07-04",
      "last_synced_at": "2026-05-22T09:41:09.015Z",
      "location_count": 2,
      "location_summary": "Carmel, Indiana • Indianapolis, Indiana",
      "locations": [
        {
          "city": "Carmel",
          "state": "Indiana"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05821309"
    },
    {
      "nct_id": "NCT02019264",
      "title": "A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Cardiovascular Disease",
        "High Cardiovascular Risk",
        "Obesity",
        "Overweight",
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "Lorcaserin hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eisai Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 14673,
      "start_date": "2014-01-24",
      "completion_date": "2018-05-14",
      "has_results": true,
      "last_update_posted_date": "2019-07-16",
      "last_synced_at": "2026-05-22T09:41:09.015Z",
      "location_count": 373,
      "location_summary": "Alexander City, Alabama • Athens, Alabama • Birmingham, Alabama + 283 more",
      "locations": [
        {
          "city": "Alexander City",
          "state": "Alabama"
        },
        {
          "city": "Athens",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02019264"
    },
    {
      "nct_id": "NCT01930214",
      "title": "Multi-center Prospective Study to Evaluate Outcomes of the Moderate to Severely Calcified Coronary Lesions (MACE)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Coronary Artery Disease"
      ],
      "interventions": [
        {
          "name": "Percutaneous Coronary Intervention",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Abbott Medical Devices",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 350,
      "start_date": "2013-09-26",
      "completion_date": "2017-06-01",
      "has_results": true,
      "last_update_posted_date": "2023-07-18",
      "last_synced_at": "2026-05-22T09:41:09.015Z",
      "location_count": 34,
      "location_summary": "Little Rock, Arkansas • Glendale, California • Hartford, Connecticut + 30 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01930214"
    },
    {
      "nct_id": "NCT01601704",
      "title": "Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Obesity",
        "Overweight"
      ],
      "interventions": [
        {
          "name": "NB32",
          "type": "DRUG"
        },
        {
          "name": "PBO",
          "type": "DRUG"
        },
        {
          "name": "Weight Management Program",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL"
      ],
      "sponsor": "Orexigen Therapeutics, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "45 Years and older"
      },
      "enrollment_count": 8910,
      "start_date": "2012-06",
      "completion_date": "2015-08",
      "has_results": true,
      "last_update_posted_date": "2017-02-27",
      "last_synced_at": "2026-05-22T09:41:09.015Z",
      "location_count": 224,
      "location_summary": "Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 221 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Scottsboro",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01601704"
    }
  ]
}